Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Burkitt Lymphoma 12Prostatic Neoplasms 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Large B-Cell, Diffuse 4Plasmablastic Lymphoma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Follicular 2Immunoblastic Lymphadenopathy 2Enteropathy-Associated T-Cell Lymphoma 2Neuroblastoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1Lymphoma, Primary Effusion 1Lymphoma, B-Cell 1Lymphoma, AIDS-Related 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Hormone-Resistant Prostate Cancer 1Hodgkin Disease 1Hematologic Neoplasms 1HIV Infections 1Composite Lymphoma 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Blast Crisis 1

Interventions

pembrolizumab 8Nivolumab 5avelumab 4Ipilimumab 4Radiotherapy 2Radiosurgery 2ALT-803 2tremelimumab 1talimogene laherparepvec 1sapanisertib 1prednylidene 1poly ICLC 1lenvatinib 1interferon gamma-1b 1epacadostat 1efineptakin alfa 1durvalumab 1deltacortene 1cemiplimab 1cabozantinib 1bempegaldesleukin 1atezolizumab 1Tacrolimus 1Radiation Dose Hypofractionation 1Radiation 1Prednisone 1Interferon-gamma 1Interferon-beta 1CTLA-4 Antigen 1B7-H1 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Merkel Cell × deltacortene × Clear all
NCT03816332 2026-04-30

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

National Cancer Institute (NCI)

Phase 1 Active not recruiting
12 enrolled 13 charts
Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡